X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (169) 169
index medicus (129) 129
male (125) 125
female (122) 122
middle aged (122) 122
adult (105) 105
aged (105) 105
life sciences (88) 88
cancer (85) 85
hematology (85) 85
oncology (82) 82
lymphomas (58) 58
rituximab (56) 56
antineoplastic combined chemotherapy protocols - therapeutic use (53) 53
treatment outcome (52) 52
aged, 80 and over (51) 51
chemotherapy (51) 51
lymphoma (50) 50
non-hodgkins-lymphoma (49) 49
prognosis (48) 48
[ sdv.can ] life sciences [q-bio]/cancer (39) 39
[sdv.can]life sciences [q-bio]/cancer (33) 33
survival (32) 32
b-cell lymphoma (31) 31
elderly-patients (31) 31
lymphoma, large b-cell, diffuse - drug therapy (31) 31
adolescent (29) 29
abridged index medicus (28) 28
disease-free survival (28) 28
hemic and lymphatic diseases (27) 27
young adult (26) 26
retrospective studies (25) 25
therapy (24) 24
care and treatment (22) 22
cyclophosphamide (22) 22
cyclophosphamide - administration & dosage (22) 22
risk factors (22) 22
survival analysis (22) 22
antineoplastic combined chemotherapy protocols - adverse effects (21) 21
expression (21) 21
follow-up studies (21) 21
doxorubicin - administration & dosage (20) 20
kaplan-meier estimate (20) 20
prospective studies (19) 19
antineoplastic agents - therapeutic use (18) 18
cyclophosphamide - therapeutic use (18) 18
neoplasm staging (18) 18
vincristine - administration & dosage (18) 18
antineoplastic combined chemotherapy protocols - administration & dosage (17) 17
doxorubicin (17) 17
lymphoma, large b-cell, diffuse - mortality (17) 17
trial (17) 17
clinical trials (16) 16
doxorubicin - therapeutic use (16) 16
fluorodeoxyglucose f18 (16) 16
immune system diseases (16) 16
lymphoma, large b-cell, diffuse - pathology (16) 16
pathology (16) 16
prednisone - administration & dosage (16) 16
prednisone - therapeutic use (16) 16
antibodies, monoclonal, murine-derived - administration & dosage (15) 15
antibodies, monoclonal, murine-derived - therapeutic use (15) 15
lymphoma, follicular - drug therapy (15) 15
antibodies, monoclonal, murine-derived (14) 14
diagnosis (14) 14
follicular lymphoma (14) 14
lymphoma, large b-cell, diffuse - diagnosis (14) 14
malignant-lymphoma (14) 14
patients (14) 14
vincristine (14) 14
[ sdv ] life sciences [q-bio] (13) 13
[sdv]life sciences [q-bio] (13) 13
analysis (13) 13
drug administration schedule (13) 13
medical research (13) 13
pet (13) 13
positron-emission tomography - methods (13) 13
positron-emission-tomography (13) 13
prednisone (13) 13
risk (13) 13
survival rate (13) 13
time factors (13) 13
follow-up (12) 12
france (12) 12
multivariate analysis (12) 12
mutation (12) 12
radiology, nuclear medicine & medical imaging (12) 12
recurrence (12) 12
transplantation (12) 12
vincristine - therapeutic use (12) 12
aggressive lymphoma (11) 11
antibodies, monoclonal - administration & dosage (11) 11
antineoplastic agents - administration & dosage (11) 11
diffuse large b-cell lymphoma (11) 11
disease (11) 11
gastroenterology & hepatology (11) 11
human health and pathology (11) 11
immunochemotherapy (11) 11
immunohistochemistry (11) 11
leukemia (11) 11
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Infectious Diseases, The, ISSN 1473-3099, 2017, Volume 17, Issue 5, pp. 510 - 519
Summary Background Listeriosis is a severe foodborne infection and a notifiable disease in France. We did a nationwide prospective study to characterise its... 
Infectious Disease | MORTALITY | MENINGITIS | INFECTIOUS DISEASES | MONOCYTOGENES | RISK-FACTORS | MANAGEMENT | GUIDELINES | SURVEILLANCE | PREGNANCY | Foodborne Diseases - microbiology | Infant, Newborn, Diseases - epidemiology | Prognosis | Prospective Studies | Humans | Listeriosis - diagnosis | Bacteremia - mortality | Male | Infant, Newborn, Diseases - microbiology | Listeriosis - epidemiology | Mandatory Reporting | Listeria monocytogenes - classification | Adult | Female | Pregnancy Complications, Infectious - microbiology | Infant, Newborn | Meningoencephalitis - epidemiology | France - epidemiology | Meningoencephalitis - mortality | Pregnancy Complications, Infectious - epidemiology | Risk Factors | Listeria monocytogenes - isolation & purification | Hospitalization | Infectious Disease Transmission, Vertical | Pregnancy | Meningoencephalitis - microbiology | Bacteremia - epidemiology | Listeriosis - microbiology | Aged | Population Surveillance | Listeriosis | Neonates | Food-borne diseases | Disease | Brain stem | Clinical trials | Infections | Genomes | Gestation | Epidemiology | Risk factors | Windows (intervals) | Listeria | Meningitis | Public health | Food | Dexamethasone | Bacterial infections | Mortality | Fetuses | Regression analysis | Clustering | Patients | Bacteremia | Meningoencephalitis | Studies | Surveillance | Medical prognosis | Health risk assessment | Cancer | Life Sciences
Journal Article
Lancet, The, ISSN 0140-6736, 2011, Volume 377, Issue 9759, pp. 42 - 51
Journal Article
Lancet, The, ISSN 0140-6736, 2016, Volume 388, Issue 10044, pp. 565 - 575
Journal Article
Lancet, The, ISSN 0140-6736, 2011, Volume 378, Issue 9806, pp. 1858 - 1867
Summary Background The outcome of diffuse large B-cell lymphoma has been substantially improved by the addition of the anti-CD20 monoclonal antibody rituximab... 
Internal Medicine | MEDICINE, GENERAL & INTERNAL | MULTICENTER | RESPONSE CRITERIA | AGGRESSIVE LYMPHOMAS | POOR-PROGNOSIS | NON-HODGKINS-LYMPHOMA | REGIMEN | YOUNG-PATIENTS | ELDERLY-PATIENTS | DES-LYMPHOMES | TRANSPLANTATION | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prospective Studies | Follow-Up Studies | Humans | Middle Aged | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Cyclophosphamide - adverse effects | Dose-Response Relationship, Drug | Young Adult | Vindesine - adverse effects | Adult | Female | Prednisolone | Doxorubicin - administration & dosage | Severity of Illness Index | Prednisone - administration & dosage | Lymphoma, Large B-Cell, Diffuse - drug therapy | Prednisone - adverse effects | Drug Administration Schedule | Risk Assessment | Rituximab | Treatment Outcome | Bleomycin - administration & dosage | Bleomycin - adverse effects | Vincristine | Lymphoma, Large B-Cell, Diffuse - mortality | Disease-Free Survival | Lymphoma, Large B-Cell, Diffuse - diagnosis | Maximum Tolerated Dose | Adolescent | Survival Analysis | Vindesine - administration & dosage | Doxorubicin - adverse effects | Chemotherapy | Physiological aspects | Lymphomas | B cells | Drug therapy | Methods | Cancer | Dehydrogenases | Toxicity | Population studies | Doxorubicin | Hepatitis | Randomization | Bleomycin | Motivation | Drug dosages | Neutropenia | Cell survival | Hematology | Prednisone | Survival | Patients | Lymphoma | Cyclophosphamide | Lymphocytes B | Monoclonal antibodies | CD20 antigen | Tumors | B-cell lymphoma | Clinical trials | Public speaking | Grants | Clinical medicine | Side effects | lymphoma | survival | International standardization | chemotherapy
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2011, Volume 12, Issue 5, pp. 460 - 468
Summary Background Diffuse large B-cell lymphoma is a common cancer in elderly patients. Although treatment has been standardised in younger patients, no... 
Hematology, Oncology and Palliative Medicine | MAINTENANCE RITUXIMAB | COLONY-STIMULATING FACTOR | PROGNOSTIC-FACTORS | RESPONSE CRITERIA | ONCOLOGY | AGGRESSIVE LYMPHOMAS | MALIGNANT-LYMPHOMAS | NON-HODGKINS-LYMPHOMA | COMPREHENSIVE GERIATRIC ASSESSMENT | DETUDE-DES-LYMPHOMES | CHOP CHEMOTHERAPY | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prognosis | Prospective Studies | Humans | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Cyclophosphamide - adverse effects | Aged, 80 and over | Vincristine - administration & dosage | Female | France | Odds Ratio | Doxorubicin - administration & dosage | Prednisone - administration & dosage | Lymphoma, Large B-Cell, Diffuse - drug therapy | Prednisone - adverse effects | Drug Administration Schedule | Lymphoma, Large B-Cell, Diffuse - pathology | Risk Assessment | Risk Factors | Rituximab | Treatment Outcome | Lymphoma, Large B-Cell, Diffuse - mortality | Disease-Free Survival | Analysis of Variance | Belgium | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Survival Analysis | Vincristine - adverse effects | Doxorubicin - adverse effects | Antibodies, Monoclonal, Murine-Derived - therapeutic use | Anthracyclines | Cyclophosphamide | Chemotherapy | Corticosteroids | Oncology, Experimental | Aged patients | Product development | Prednisone | Lymphomas | Research | Cancer | Toxicity | Albumin | Clinical trials | Multivariate analysis | Doxorubicin | Survival | Vincristine | Side effects | Motivation | Age | rituximab | B-cell lymphoma | Geriatrics | Neutropenia
Journal Article